

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

PROFESSIONAL INFORMATION

SCHEDULING STATUS:

S4

1. NAME OF THE MEDICINE

XIGDUO® XR 5 mg/ 500 mg, film-coated tablets

XIGDUO® XR 5 mg/ 1000 mg, film-coated tablets

XIGDUO® XR 10 mg/ 500 mg, film-coated tablets

XIGDUO® XR 10 mg/ 1000 mg, film-coated tablets

XIGDUO XR IS CONTRAINDICATED FOR USE IN TYPE 1 DIABETES. XIGDUO XR IS NOT INDICATED FOR USE IN WEIGHT CONTROL PROGRAMMES.

There have been reports of metabolic acidosis, including ketoacidosis, which were serious life-threatening or fatal, in patients taking component medicine of XIGDUO XR. Patients who present with signs and symptoms including nausea, vomiting, abdominal pain, malaise and shortness of breath, should be assessed for metabolic acidosis, even if blood glucose levels are below 11 mmol/L. XIGDUO XR should be discontinued and the patient should be promptly evaluated and managed accordingly. Predisposing factors for metabolic acidosis include insulin dose reduction, reduced caloric intake, reduced fluid intake or increased insulin requirements due to infections, illness, surgery or alcohol abuse. Caution is advised in treating these patients with XIGDUO XR.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

XIGDUO XR 5 mg/ 500 mg: Each film-coated tablet contains 5 mg dapagliflozin as dapagliflozin propanediol and 500 mg metformin HCl extended-release.

XIGDUO XR 5 mg/ 1000 mg: Each film-coated tablet contains 5 mg dapagliflozin as dapagliflozin propanediol and 1000 mg metformin HCl extended-release.

XIGDUO XR 10 mg/ 500 mg: Each film-coated tablet contains 10 mg dapagliflozin as dapagliflozin propanediol and 500 mg metformin HCl extended-release.

XIGDUO XR 10 mg/ 1000 mg: Each film-coated tablet contains 10 mg dapagliflozin as dapagliflozin propanediol and 1000 mg metformin HCl extended-release.

Contains lactose (anhydrous). For excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablets.

XIGDUO XR 5 mg/ 500 mg tablets are orange, capsule shaped, film-coated tablets debossed with “1070” and “5/500” on one side and plain on the other side.

The dimension is approximately 19.8 mm x 10.2 mm x 7.2 mm.

XIGDUO XR 5 mg/ 1000 mg tablets are pink to dark pink, biconvex, oval shaped, film-coated tablets debossed with “1071” and “5/1000” on one side and plain on the other side.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

The dimension is approximately 20.3 mm x 10.8 mm x 8.0 mm.

XIGDUO XR 10 mg/ 500 mg tablets are pink, biconvex, capsule shaped, film-coated tablets debossed with “1072” and “10/500” on one side and plain on the other side.

The dimension is approximately 19.8 mm x 10.2 mm x 7.2 mm.

XIGDUO XR 10 mg/ 1000 mg tablets are yellow to dark yellow, biconvex, oval shaped, film-coated tablets debossed with “1073” and “10/1000” on one side and plain on the other side.

The dimension is approximately 20.3 mm x 10.8 mm x 8.0 mm.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

XIGDUO XR is indicated in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate:

- for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise.
- to reduce the risk of developing new or worsening existing heart failure or cardiovascular death in Type 2 diabetic mellitus patients with established cardiovascular (CV) disease or multiple CV risk factors.

4.2 Posology and method of administration

Posology

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

The recommended dose of dapagliflozin is 10 mg once daily. The recommended starting dose of metformin is 500 mg once daily, which can be titrated to 2000 mg once daily, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.

In patients treated with metformin, the dose of XIGDUO XR should provide metformin at the dose already being taken, or the nearest therapeutically appropriate dose.

If no adequate strength of XIGDUO XR is available, individual mono-components should be used instead of the fixed dose combination.

It is recommended to not exceed a dose of dapagliflozin 10 mg daily (two tablets of 5 mg dapagliflozin / 500 mg metformin or two tablets of 5 mg dapagliflozin / 1000 mg metformin).

Special populations

Patients with renal impairment

Assess renal function prior to initiation of XIGDUO XR and periodically thereafter (see section 4.4 and 5.2).

Renal impaired patients may have a higher incidence of adverse events.

Table 1 Dosage in patients with renal impairment

eGFR ml/min/ 1,73 m ²	Metformin XR	Dapagliflozin
60-89	Maximum daily dose is 2000 mg. Dose reduction may be considered in relation to declining	Maximum total daily dose is 10mg.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd
 Product Name: XIGDUO® XR
 Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
 10 mg/500 mg, 10 mg/1000 mg (Tablet)
 Registration numbers: 52/21.2/0414; 52/21.2/0415;
 52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved
 Date of approval: 12 February 2025

	renal function.	
45-59	Maximum daily dose is 2000 mg. The starting dose is at most half of the maximum dose.	Maximum total daily dose is 10 mg.
30-44	Maximum daily dose is 1000 mg. The starting dose is at most half of the maximum dose.	Dapagliflozin is not recommended when eGFR is persistently below 45 mL/min/1.73 m ² .
<30	Metformin is contraindicated	Dapagliflozin is contraindicated.

Mild renal impairment

No dose adjustment of XIGDUO XR is required for patients with mild renal impairment (eGFR 60-89 mL/min/1,73 m² by Modified Diet in Renal Disease [MDRD] eGFR equation).

Moderate renal impairment

XIGDUO XR is not recommended for the treatment of diabetes in patients with eGFR persistently below 45 mL/min/1,73 m² (see section 4.4). No dose adjustment is required for patients with eGFR ≥ 45 mL/min/1,73 m²).

Severe renal impairment

Due to the metformin component, XIGDUO XR is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1,73 m²) (see section 4.3).

Patients with hepatic impairment

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Since impaired hepatic function has been associated with some cases of lactic acidosis in patients taking metformin, XIGDUO XR should generally be avoided in patients with clinical or laboratory evidence of hepatic impairment (see section 4.4).

Elderly patients

Because metformin is eliminated by the kidneys, and because elderly patients are more likely to have decreased renal function, XIGDUO XR should be used with caution as age increases. The renal function recommendations provided for all patients also apply to elderly patients (see section 4.4).

Paediatric population

The safety and efficacy of XIGDUO XR in paediatric and adolescent patients have not been established. No data are available.

Method of administration

XIGDUO XR should be taken orally, once daily with the evening meal.

Patients should be informed that XIGDUO XR tablets must be swallowed whole and never crushed, cut, or chewed. Occasionally, the inactive ingredients of XIGDUO XR will be eliminated in the faeces as a soft, hydrated mass that may resemble the original tablet.

4.3 Contraindications

XIGDUO XR is contraindicated in patients with:

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

-
- Patients with a history of any serious hypersensitivity reaction to dapagliflozin, metformin hydrochloride or to any of the excipients.
 - Severe renal impairment [(metformin component)] (eGFR < 30 mL/min/1,73 m²).
 - Acute or chronic metabolic acidosis including diabetic ketoacidosis.
 - Diabetes mellitus Type 1.
 - Pregnant women or women who are breast-feeding their infants (See section 4.6).

4.4 Special warnings and precautions for use

Lactic acidosis

Metformin hydrochloride

Lactic acidosis is a very rare, but serious and potentially fatal in the absence of prompt treatment, metabolic complication that can occur due to metformin accumulation (metformin plasma levels generally > 5 mcg/l). Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis. Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure. The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency, dehydration, any acute conditions associated with hypoxia or impacting renal function (see section 4.4).

Medicines that can acutely impair renal function, such as antihypertensives, diuretics and NSAIDs, should be initiated with caution in metformin-treated patients (see section 4.5).

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Patients and/or caregivers should be informed on the risk of lactic acidosis. Lactic acidosis is characterized by symptoms such as acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. Diagnostic laboratory findings are decreased blood pH, plasma lactate levels above 5 mmol/L, and an increased anion gap and lactate/pyruvate ratio. If lactic acidosis is suspected, treatment with XIGDUO XR should be discontinued and the patient hospitalized immediately.

Use in patients with renal impairment

XIGDUO XR is not recommended for the treatment of diabetes in patients with eGFR persistently below 45 mL/min/1,73 m² as the glycaemic efficacy of dapagliflozin is dependent on renal function (see section 4.2.3). The maximum dose of metformin in patients with an eGFR of 30 to less than 45 mL/min/1,73 m² is 1000 mg once daily.

Due to metformin, XIGDUO XR is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1,73 m²) (see section 4.3).

Metformin is excreted by the kidney and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function (see section 4.4).

Assess renal function prior to initiation of XIGDUO XR and then periodically thereafter:

- at least annually
- at least two to four times a year in patients with renal function where eGFR levels are approaching 45 mL/min/1,73 m² and in elderly patients.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Acute conditions associated with hypoxia or impacting renal function

Metformin hydrochloride

Cardiovascular collapse (shock), acute congestive heart failure, acute myocardial infarction, and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause pre-renal azotemia. Acute conditions such as dehydration, severe infections, and hypoperfusion, have potential to alter renal function. In these situations, metformin must be discontinued.

Radiologic studies with intravascular iodinated contrast materials

Metformin hydrochloride

Intravascular administration of iodinated contrast agents in radiological studies can lead to an acute decrease in renal function and has been associated with lactic acidosis in patients receiving metformin. XIGDUO XR should temporarily be discontinued prior to, or at the time of the procedure and not reinstituted until 48 hours afterwards and only after renal function has been re-evaluated and found to be stable.

Surgical procedures

Metformin hydrochloride

Use of XIGDUO XR should be temporarily suspended before any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as stable.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

The patient should receive regular monitoring of their blood glucose with the administration of soluble insulin perioperatively as indicated.

Use in patients with hepatic impairment

Metformin hydrochloride

Since impaired hepatic function has been associated with some cases of metformin-associated lactic acidosis, XIGDUO XR should be avoided in patients with clinical or laboratory evidence of hepatic disease.

Excessive alcohol intake

Metformin hydrochloride

Alcohol potentiates the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake while receiving XIGDUO XR.

Ketoacidosis

Dapagliflozin

There have been reports of ketoacidosis, including diabetic ketoacidosis, in patients with type 1 and type 2 diabetes mellitus taking dapagliflozin and other SGLT2 inhibitors. XIGDUO XR is not indicated for the treatment of patients with type 1 diabetes mellitus.

Patients treated with XIGDUO XR who present with signs and symptoms consistent with ketoacidosis, including nausea, vomiting, abdominal pain, malaise and shortness of breath should be assessed for ketoacidosis, even if blood glucose levels are below 14 mmol/L (250

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

mg/dL). If ketoacidosis is suspected, discontinuation or temporary interruption of XIGDUO XR should be considered and the patient should be promptly evaluated.

Predisposing factors to ketoacidosis include a low beta-cell function reserve resulting from pancreatic disorders (e.g., type 1 diabetes, history of pancreatitis or pancreatic surgery), insulin dose reduction, reduced caloric intake or increased insulin requirements due to infections, illness, surgery or alcohol abuse. XIGDUO XR should be used with caution in these patients.

Change in clinical status of patients with previously controlled type 2 diabetes

A patient with type 2 diabetes previously well controlled on XIGDUO XR who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes, urine and serum ketones, blood glucose, blood pH, lactate, pyruvate, and metformin levels. If acidosis of either form occurs, XIGDUO XR must be stopped immediately, and other appropriate corrective measures initiated.

Use in patients at risk for volume depletion

Dapagliflozin

Due to its mechanism of action, dapagliflozin induces osmotic diuresis which may lead to modest decrease in blood pressure (see section 5.1). Temporary interruption of XIGDUO XR should be considered for patients who develop volume depletion.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Use with medications known to cause hypoglycaemia

Dapagliflozin

Insulin and insulin secretagogues, such as sulfonylureas, cause hypoglycaemia. Therefore, a lower dose of insulin or the insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with dapagliflozin (see section 5.1).

Metformin hydrochloride

Hypoglycaemia does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycaemic effects. Hypoglycaemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking medicines.

Lactose

XIGDUO XR contains lactose. Patients with rare hereditary problems of galactose intolerance, e.g. galactosaemia, Lapp lactase deficiency, glucose-galactose malabsorption or fructose intolerance should not take XIGDUO XR.

Vitamin B12 decrease/deficiency

Metformin hydrochloride

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

Metformin may reduce vitamin B12 serum levels. The risk of low vitamin B12 levels increases with increasing metformin dose, treatment duration, and/or in patients with risk factors known to cause vitamin B12 deficiency. In case of suspicion of vitamin B12 deficiency (such as anemia or neuropathy), vitamin B12 serum levels should be monitored. Periodic vitamin B12 monitoring could be necessary in patients with risk factors for vitamin B12 deficiency. Metformin therapy should be continued for as long as it is tolerated and not contraindicated and appropriate corrective treatment for vitamin B12 deficiency provided in line with current clinical guidelines.

4.5 Interaction with other medicines and other forms of interaction

Interaction with dapagliflozin and metformin

Coadministration of multiple doses of dapagliflozin and metformin did not meaningfully alter the pharmacokinetics of either dapagliflozin or metformin in healthy subjects.

There have been no formal interaction studies for XIGDUO XR. The following statements reflect the information available on the individual active substances.

Drug interactions with dapagliflozin

The metabolism of dapagliflozin is primarily mediated by UGT1A9-dependent glucuronide conjugation. The major metabolite, dapagliflozin 3-O-glucuronide, is not an SGLT2 inhibitor.

In in vitro studies, dapagliflozin and dapagliflozin 3-O-glucuronide neither inhibited CYP1A2, 2C9, 2C19, 2D6, 3A4, nor induced CYP1A2, 2B6 or 3A4. Therefore, dapagliflozin is not expected to alter the metabolic clearance of co-administered medicines that are metabolized

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

by these enzymes, and medicines that inhibit or induce these enzymes are not expected to alter the metabolic clearance of dapagliflozin. Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter and dapagliflozin 3-O-glucuronide is a substrate for the OAT3 active transporter. Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. Overall, dapagliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are P-gp, OCT2, OAT1, or OAT3 substrates.

Effect of other medicines on dapagliflozin

In interaction studies conducted in healthy subjects, using mainly single dose design, the pharmacokinetics properties of dapagliflozin were not altered by metformin (an hOCT-1 and hOCT-2 substrate), pioglitazone (a CYP2C8 [major] and CYP3A4 [minor] substrate), sitagliptin (an hOAT-3 substrate and P-glycoprotein substrate), glimepiride (a CYP2C9 substrate), voglibose (an α -glucosidase inhibitor), hydrochlorothiazide, bumetanide, valsartan, or simvastatin (a CYP3A4 substrate). Therefore, meaningful interaction of dapagliflozin with other substrates of hOCT-1, hOCT-2, hOAT-3, P-gp, CYP2C8, CYP2C9, CYP3A4, and other α -glucosidase inhibitors would not be expected.

Following coadministration of dapagliflozin with rifampicin (an inducer of various active transporters and drug-metabolizing enzymes) or mefenamic acid (an inhibitor of UGT1A9), a 22 % decrease and a 51 % increase, respectively, in dapagliflozin systemic exposure was seen, but with no clinically meaningful effect on 24-hour urinary glucose excretion in either case.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Coadministration of dapagliflozin and bumetanide did not meaningfully change the pharmacodynamic effect of dapagliflozin to increase urinary glucose excretion in healthy subjects.

Effect of dapagliflozin on other medicines

Concomitant use of dapagliflozin and lithium may lead to a reduction in serum lithium concentrations due to a possible increased urinary clearance of lithium. The dose of lithium may need to be adjusted.

In interaction studies conducted in healthy subjects, using mainly a single dose design, dapagliflozin did not alter the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, simvastatin, digoxin (a P-gp substrate), or warfarin (S-warfarin is a CYP2C substrate). Therefore, dapagliflozin is not a clinical meaningful inhibitor of hOCT-1, hOCT-2, hOAT-3, P-gp transporter pathway, and CYP2C8, CYP2C9, CYP2C19 and CYP3A4 mediated metabolism.

Coadministration of dapagliflozin and bumetanide did not meaningfully alter the steady-state pharmacodynamic responses (urinary sodium excretion, urine volume) to bumetanide in healthy subjects.

Dapagliflozin did not affect the anticoagulant activity of warfarin as measured by the prothrombin time (International Normalized Ratio [INR]).

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

Interactions between metformin hydrochloride and other medicines

Cationic medicines

Cationic medicines (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such interaction between metformin and oral cimetidine has been observed in normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug-interaction studies, with a 60 % increase in peak metformin plasma and whole blood concentrations and a 40 % increase in plasma and whole blood metformin AUC. There was no change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine pharmacokinetics. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of metformin and/or the interfering medicine is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.

Glyburide

In a single-dose interaction study in type 2 diabetic patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. Decreases in glyburide AUC and maximum concentration (C_{max}) were observed but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects make the clinical significance of this interaction uncertain.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

Furosemide

A single-dose, metformin-furosemide drug-interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration. Furosemide increased the metformin plasma and blood C_{max} by 22 % and blood AUC by 15 %, without any significant change in metformin renal clearance. When administered with metformin, the C_{max} and AUC of furosemide were 31 % and 12 % smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32 %, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when co-administered chronically.

Nifedipine

A single-dose, metformin-nifedipine drug-interaction study in normal healthy volunteers demonstrated that coadministration of nifedipine increased plasma metformin C_{max} and AUC by 20 % and 9 %, respectively, and increased the amount excreted in the urine. T_{max} and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine.

Use with other medicines

Certain medicines tend to produce hyperglycaemia and may lead to loss of glycaemic control. These medicines include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking medicines, and isoniazid. When such

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

medicines are administered to a patient receiving metformin, the patient should be closely observed for loss of blood glucose control. When such medicines are withdrawn from a patient receiving metformin, the patient should be observed closely for hypoglycaemia.

In healthy volunteers, the pharmacokinetics of metformin and propranolol, and metformin and ibuprofen was not affected when co-administered in single-dose interaction studies.

Metformin is negligibly bound to plasma proteins and, therefore, is less likely to interact with highly protein-bound medicines such as salicylates, sulphonamides, chloramphenicol, and probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.

Other interactions

The effects of smoking, diet, herbal products, and alcohol use on the pharmacokinetics of dapagliflozin have not been specifically studied.

Interference with 1,5-anhydroglucitol (1,5-AG) Assay

Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycaemic control.

4.6 Fertility, pregnancy and lactation

Pregnancy

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

XIGDUO XR is contraindicated in pregnancy. When pregnancy is detected XIGDUO XR should be discontinued.

In the time period corresponding to second and third trimester of pregnancy with respect to human renal maturation, maternal exposure to dapagliflozin in rat studies was associated with increased incidence and/or severity of renal pelvic and tubular dilatations in progeny (see section 5.3).

There are no adequate and well-controlled studies of XIGDUO XR in pregnant women.

Breastfeeding

XIGDUO XR must not be used by a nursing woman.

No studies in lactating animals have been conducted with the combined components of XIGDUO XR. In studies performed with the individual components, both dapagliflozin and metformin are excreted in the milk of lactating rats.

Direct and indirect exposure of dapagliflozin to weanling juvenile rats and during late pregnancy are each associated with increased incidence and/or severity of renal pelvic and tubular dilatations in progeny, although the long-term functional consequences of these effects are unknown. These periods of exposure coincide with a critical window of renal maturation in rats. As functional maturation of the kidneys in humans continues in the first 2 years of life, dapagliflozin-associated dilated renal pelvis and tubules noted in juvenile rats could constitute potential risk for human renal maturation during the first 2 years of life. Additionally, the negative effects on body-weight gain associated with lactational exposure in

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

weanling juvenile rats suggest that dapagliflozin must be avoided during the first 2 years of life (see section 5.3).

Fertility

The effect of XIGDUO XR on human fertility has not been studied.

4.7 Effects on ability to drive and use machines

Patients must bear in mind the possibility of hypoglycaemia and its effects on their motor skills.

4.8 Undesirable effects

a. Summary of the safety profile

Dapagliflozin + metformin

Data from a pre-specified pool of patients from 8 short-term, placebo-controlled studies of dapagliflozin co-administered with metformin immediate- or extended-release was used to evaluate safety data. This pool included several add-on studies (metformin alone and in combination with a DPP4 inhibitor and metformin, or insulin and metformin, 2 initial combination with metformin studies, and 2 studies of patients with cardiovascular disease (CVD) and type 2 diabetes who received their usual treatment (with metformin as background therapy)). For studies that included background therapy with and without metformin, only patients who received metformin were included in the 8-study placebo-controlled pool. Across these 8 studies 983 patients were treated once daily with dapagliflozin 10 mg and metformin and 1 185 were treated with placebo and metformin.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

These 8 studies provide a mean duration of exposure of 23 weeks. The mean age of the population was 57 years and 2 % were older than 75 years. Fifty-four percent (54 %) of the population was male; 88 % White, 6 % Asian, and 3 % Black or African American. At baseline, the population had diabetes for an average of 8 years, mean haemoglobin A1c (HbA1c) was 8,4 %, and renal function was normal or mildly impaired in 90 % of patients and moderately impaired in 10 % of patients.

Dapagliflozin

The safety profile of dapagliflozin in type 2 diabetes mellitus has been evaluated in clinical studies including more than 15 000 subjects treated with dapagliflozin. For further information about the clinical studies, see section 5.1.

The incidence of adverse reactions was determined using a pre-specified pool of patients from 13 short-term (mean duration 22 weeks), placebo-controlled studies in type 2 diabetes. Across these 13 studies, 2 360 patients were treated once daily with dapagliflozin 10 mg and 2 295 were treated with placebo (either as monotherapy or in combination with other antidiabetic therapies).

Additionally, dapagliflozin 5 mg was evaluated in a 12-study, short-term, placebo-controlled pool of patients that included 1 145 patients treated with dapagliflozin 5 mg (mean exposure = 22 weeks) and 1 393 patients treated with (mean exposure = 21 weeks), either as monotherapy or in combination with other antidiabetic therapies.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

In the dedicated cardiovascular (CV) outcomes study in patients with type 2 diabetes mellitus, 8 574 patients received dapagliflozin 10 mg and 8 569 received placebo for a median exposure time of 48 months. In total, there were 30 623 patient-years of exposure to dapagliflozin.

The adverse reactions in patients treated with dapagliflozin 10 mg with and without metformin in clinical trials in type 2 diabetes mellitus and post marketing are shown in Table 2 and Table 3 respectively.

Frequencies of occurrence of adverse reactions are defined as: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1\ 000$ to $< 1/100$); rare ($\geq 1/10\ 000$ to $< 1/1\ 000$); very rare ($< 1/10\ 000$); not known (cannot be estimated from the available data).

Table 2 Adverse Drug Reactions by Frequency and System Organ Class (SOC) in clinical trials.

System Organ Class	Common	Rare
Infections and Infestations	Genital infection ^{a,b} Urinary tract infection ^{a,c}	
Metabolism and Nutrition Disorders		Diabetic ketoacidosis ^f
Musculoskeletal and Connective Tissue Disorders	Back pain ^d	

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

System Organ Class	Common	Rare
Renal and Urinary Disorders	Pollakiuria ^a and polyuria ^{a,e}	

^a Identified from 8 placebo-controlled studies, including 2 initial combination with metformin, 2 add-on to metformin, 1 add-on to insulin, 1 add-on to sitagliptin, and 2 studies with combination add-on therapy.

^b Multiple adverse events terms, including vulvovaginal infections and candidiasis, balanoposthitis, balanitis candida, penile abscess, penile infection, vulval abscess and vaginitis bacterial.

^c Multiple adverse events terms, including genitourinary tract infection, cystitis, pyelonephritis, trigonitis, urethritis and prostatitis.

^d Additional events identified from 13 placebo-controlled studies with dapagliflozin 10 mg in type 2 diabetes mellitus including 3 monotherapy, 1 initial combination with metformin, 2 add-on to metformin, 2 add-on to insulin, 1 add-on to pioglitazone, 1 add-on to sitagliptin, 1 add-on to glimepiride, and 2 studies with combination add-on therapy.

^e Represents multiple adverse events terms, including polyuria, urine output increased.

^f Identified from the cardiovascular outcomes study in patients with type 2 diabetes.

Frequency is based on annual rate.

Table 3 Post-marketing experience

System Organ Class	Unknown
Skin and subcutaneous tissue disorders	Rash ^{a,b}

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,

Date of approval: 12 February 2025

10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;

52/21.2/0412; 52/21.2/0413

^a Identified during post marketed use of dapagliflozin. Because these reactions are reported voluntarily from a population of an uncertain size, it is not always possible to reliably estimate their frequency.

^b Rash includes the following preferred terms, listed in order of frequency in clinical trials:

Rash, generalized rash, pruritic rash, macular rash, maculo-papular rash, pustular rash,

vesicular rash, erythematous rash. In active- and placebo-controlled clinical trials

(dapagliflozin, n=5 936, All control, n=3 403), the frequency of Rash was similar for

dapagliflozin (1,4 %) and All control (1,4 %), respectively, corresponding to the frequency

'Common'.

Clinical trial and post-market data – metformin hydrochloride

Table 4 presents adverse reactions by system organ class and by frequency category.

Frequency categories are based on information available from the metformin Summary of

Product Characteristics available in the EU.

Table 4 The Frequency of Metformin Adverse Reactions Identified from Clinical Trial and Post marketing Data

System Organ Class	Very common	Common	Very rare
Metabolism and Nutrition Disorders		Vitamin B12 decrease/deficiency	Lactic acidosis
Nervous System Disorders		Taste disturbance	

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

System Organ Class	Very common	Common	Very rare
Gastrointestinal Disorders	Gastro-intestinal symptoms ^a		
Hepatobiliary Disorders			Liver function disorders, hepatitis
Skin and Subcutaneous Tissue Disorders			Urticaria, erythema, pruritus

^a Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain, and loss of appetite occur most frequently during initiation of therapy and resolve spontaneously in most cases.

b. Description of selected adverse reactions

Genital Infections

Events of genital infections were reported in 5,5 % and 0,6 % of patients who received dapagliflozin 10 mg and placebo, respectively, in the 13-study, short-term, placebo-controlled pool. The events of genital infections reported in patients treated with dapagliflozin 10 mg were all mild to moderate. Most events of genital infection responded to an initial course of standard treatment and rarely resulted in discontinuation from the study (0,2 % dapagliflozin 10 mg vs. 0 % in placebo). Infections were reported more frequently in females (8,4 % dapagliflozin 10 mg vs. 1,2 % placebo) than in males (3,4 % dapagliflozin 10 mg vs. 0,2 % placebo). The most frequently reported genital infections were vulvovaginal mycotic infections in females, and balanitis in males.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,

Date of approval: 12 February 2025

10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;

52/21.2/0412; 52/21.2/0413

In the CV outcomes study, the number of patients with serious adverse events (SAE) of genital infections were few and balanced: 2 (< 0,1 %) patients in each of the dapagliflozin and placebo groups.

Urinary Tract Infections

Events of urinary tract infections (UTI) were reported in 4,7 % and 3,5 % of patients who received dapagliflozin 10 mg and placebo, respectively, in the 13-study, short-term, placebo-controlled pool. Most events of urinary tract infections reported in patients treated with dapagliflozin 10 mg were mild to moderate. Most patients responded to an initial course of standard treatment, and urinary tract infections rarely caused discontinuation from the study (0,2 % dapagliflozin 10 mg vs. 0,1 % placebo). Infections were more frequently reported in females (8,5 % dapagliflozin 10 mg vs. 6,7 % placebo) than in males (1,8 % dapagliflozin 10 mg vs. 1,3 % placebo).

In the CV outcomes study, there were fewer patients with SAEs of UTI in the dapagliflozin group compared with the placebo group: 79 (0,9 %) and 109 (1,3 %), respectively.

Diabetic ketoacidosis (DKA) and Atypical ketoacidosis

In the CV outcomes study with a median exposure time of 48 months, events of DKA were reported in 27 patients in the dapagliflozin 10 mg group and 12 patients in the placebo group. The events occurred evenly distributed over the study period. Of the 27 patients with DKA events in the dapagliflozin group, 22 had concomitant insulin treatment at the time of

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

the event. Precipitating factors for DKA were as expected in a type 2 diabetes mellitus population (see section 4.4).

There have been reports of atypical ketoacidosis associated with dapagliflozin. In such cases, hyperglycaemia may be limited or absent; patient's ketone levels should be monitored.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to SAHPRA via "6.04 Adverse Drug Reactions Reporting Form", found online under SAHPRA's publications: <https://www.sahpra.org.za/Publications/Index/8>

4.9 Overdose

Dapagliflozin

Orally administered dapagliflozin has been shown to be safe and well-tolerated in healthy subjects at single doses up to 500 mg (50 times the MRHD).

In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient's clinical status. The removal of dapagliflozin by haemodialysis has not been studied.

Metformin hydrochloride

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

High overdose or concomitant risks of metformin may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in a hospital. The most effective method to remove lactate and metformin is haemodialysis. Events of hypoglycaemia have been reported with overdoses of metformin.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Pharmacological Classification

A 21.2 Oral hypoglycaemics

Mechanism of action

XIGDUO XR combines two antihyperglycaemic medicines with complementary mechanisms of action to improve both fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) in patients with type 2 diabetes mellitus: dapagliflozin, an SGLT2 inhibitor, and metformin hydrochloride, a biguanide.

Dapagliflozin

Dapagliflozin is a potent, selective, and reversible inhibitor of sodium glucose cotransporter 2 (SGLT2) that improves glycaemic control in patients with diabetes mellitus and provides cardio-renal benefits.

Inhibition of SGLT2 by dapagliflozin reduces reabsorption of glucose from the glomerular filtrate in the proximal renal tubule with a concomitant reduction in sodium reabsorption

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

leading to urinary excretion of glucose and osmotic diuresis. Dapagliflozin therefore increases the delivery of sodium to the distal tubule which is believed to increase tubuloglomerular feedback and reduce intraglomerular pressure. Secondary effects of SGLT2 inhibition with dapagliflozin also include a modest reduction in blood pressure, reduction in body weight, and an increase in hematocrit.

The cardio-renal benefits of dapagliflozin are not solely dependent on the blood glucose-lowering effect. In addition to the osmotic diuretic and related hemodynamic actions of SGLT2 inhibition, potential secondary effects on myocardial metabolism, ion channels, fibrosis, adipokines and uric acid may be mechanisms underlying the cardio-renal beneficial effects of dapagliflozin.

Dapagliflozin improves both fasting and postprandial plasma glucose levels. This glucose excretion (glucuretic effect) is observed after the first dose, is continuous over the 24-hour dosing interval, and is sustained for the duration of treatment. The amount of glucose removed by the kidney through this mechanism is dependent upon the blood glucose concentration and GFR. Thus, in healthy subjects with normal glucose, dapagliflozin has a low propensity to cause hypoglycaemia. Dapagliflozin does not impair normal endogenous glucose production in response to hypoglycaemia. Dapagliflozin acts independently of insulin secretion and insulin action. Over time, improvement in beta-cell function (HOMA-2) has been observed in clinical studies with dapagliflozin.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

The majority of weight reduction is body-fat loss, including visceral fat rather than lean tissue or fluid loss as demonstrated by dual energy x-ray absorptiometry (DXA) and magnetic resonance imaging.

SGLT2 is selectively expressed in the kidney.

Dapagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is greater than 1 400 times more selective for SGLT2 versus SGLT1, the major transporter in the gut responsible for glucose absorption.

Metformin hydrochloride

Metformin is an antihyperglycaemic medicine which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose.

Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Unlike sulfonylureas, metformin does not produce hypoglycaemia in either patients with type 2 diabetes mellitus or normal subjects (except in special circumstances, see section 4.4) and does not cause hyperinsulinaemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

Pharmacodynamic effects

Dapagliflozin

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin. Approximately 70 g of glucose was excreted in the urine per day (corresponding to 280 kcal/day) at a dapagliflozin dose of 10 mg/day in patients with type 2 diabetes mellitus for 12 weeks. This glucose elimination rate approached the maximum glucose excretion observed at 20 mg/day of dapagliflozin. Evidence of sustained glucose excretion was seen in patients with type 2 diabetes mellitus given dapagliflozin 10 mg/day for up to 2 years.

This urinary glucose excretion with dapagliflozin also results in osmotic diuresis and increases in urinary volume. Urinary volume increases in patients with type 2 diabetes mellitus treated with dapagliflozin 10 mg were sustained at 12 weeks and amounted to approximately 375 mL/day. The increase in urinary volume was associated with a small and transient increase in urinary sodium excretion that was not associated with changes in serum sodium concentrations.

Urinary uric acid excretion was also increased transiently (for 3-7 days) and accompanied by a reduction in serum uric acid concentration. At 24 weeks, reductions in serum uric acid concentrations ranged from -0,0483 mmol/L to -0,0183 mmol/L.

5.2 Pharmacokinetic properties

XIGDUO XR combination tablets are considered to be bioequivalent to coadministration of corresponding doses of dapagliflozin and metformin hydrochloride XR administered together as individual tablets.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

The administration of XIGDUO XR in healthy subjects after a standard meal compared to the fasted state results in the same extent of exposure for both dapagliflozin and metformin XR. Compared to the fasted state, the standard meal results in 35 % reduction and a delay of 1 to 2 hours in the peak plasma concentrations of dapagliflozin. This effect of food is not considered to be clinically meaningful.

Absorption

Dapagliflozin

Dapagliflozin is rapidly and well absorbed after oral administration and can be administered with or without food. Maximum dapagliflozin plasma concentrations ($C_{\max}$) are usually attained within 2 hours after administration in the fasted state. The $C_{\max}$ and AUC values increase proportionally to the increment in dapagliflozin dose. The absolute oral bioavailability of dapagliflozin following the administration of a 10 mg dose is 78 %.

Metformin hydrochloride

Following a single oral dose of metformin extended-release, $C_{\max}$ is achieved with a median value of 7 hours and a range of 4 to 8 hours. At steady state, the AUC and $C_{\max}$ are less than dose proportional for metformin extended-release within the range of 500 to 2 000 mg administered once daily. Peak plasma levels are approximately 0,6, 1,1, 1,4, and 1,8 µg/mL for 500, 1 000, 1 500, and 2 000 mg once-daily doses, respectively.

Distribution

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

Dapagliflozin

Dapagliflozin is approximately 91 % protein bound. Protein binding is not altered in various disease states (e.g renal or hepatic impairment).

Metformin hydrochloride

Distribution studies with extended-release metformin have not been conducted; however, the apparent volume of distribution (V/F) of metformin following single oral doses of immediate release metformin 850 mg averages 654 ± 358 L. Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90 % protein bound. Metformin partitions into erythrocytes, most likely as a function of time.

Metabolism

Dapagliflozin

Dapagliflozin is a C-linked glucoside, meaning the aglycone component is attached to glucose by a carbon-carbon bond, thereby conferring stability against glucosidase enzymes.

The mean plasma terminal half-life ($t_{1/2}$) for dapagliflozin is 12,9 hours following a single oral dose of dapagliflozin 10 mg to healthy subjects. Dapagliflozin is extensively metabolized primarily to yield dapagliflozin 3-O-glucuronide, which is an inactive metabolite. Dapagliflozin 3-O-glucuronide accounts for 61 % of a 50 mg [^{14}C]-dapagliflozin dose and is the predominant drug-related component in human plasma, accounting for 42 % (based on AUC [0-12 h]) of total plasma radioactivity, similar to the 39 % contribution by parent compound.

Based on AUC, no other metabolite accounts for > 5 % of the total plasma radioactivity.

Dapagliflozin 3-O-glucuronide or other metabolites do not contribute to the glucose-lowering

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

effects. The formation of dapagliflozin 3-O-glucuronide is mediated by UGT1A9, an enzyme presents in the liver and kidney, and CYP mediated metabolism is a minor clearance pathway in humans.

Metformin hydrochloride

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) or biliary excretion. Metabolism studies with extended-release metformin tablets have not been conducted.

Excretion

Dapagliflozin

Dapagliflozin and related metabolites are primarily eliminated via urinary excretion, of which less than 2 % is unchanged dapagliflozin. After administration of 50 mg [14C]-dapagliflozin dose, 96 % is recovered, 75 % in urine and 21 % in faeces. In faeces, approximately 15 % of the dose is excreted as parent compound.

Metformin hydrochloride

Renal clearance is approximately 3,5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90 % of the absorbed compound is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6,2 hours.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

In blood, the elimination half-life is approximately 17,6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

Special populations

Renal Impairment

Dapagliflozin

For dosing recommendations for patients with moderate to severe renal impairment see section 4.2. At steady-state (20 mg once-daily dapagliflozin for 7 days), patients with type 2 diabetes mellitus and mild, moderate or severe renal impairment (as determined by iothexol clearance) had mean systemic exposures of dapagliflozin that were 32 %, 60 % and 87 % higher, respectively, than those of patients with type 2 diabetes mellitus and normal renal function. At dapagliflozin 20 mg once-daily, higher systemic exposure to dapagliflozin in patients with type 2 diabetes mellitus and renal impairment did not result in a correspondingly higher renal glucose clearance or 24-hour glucose excretion. The renal-glucose clearance and 24-hour glucose excretion was lower in patients with moderate or severe renal impairment as compared to patients with normal and mild renal impairment. The steady-state 24-hour urinary glucose excretion was highly dependent on renal function and 85, 52, 18, and 11 g of glucose/day was excreted by patients with type 2 diabetes mellitus and normal renal function or mild, moderate, or severe renal impairment, respectively. There were no differences in the protein binding of dapagliflozin between renal impairment groups or compared to healthy subjects. The impact of haemodialysis on dapagliflozin exposure is not known.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

Metformin hydrochloride

In patients with renal impairment, the plasma and blood half-life of metformin is prolonged in proportion to the decrease in renal function.

Hepatic Impairment

Dapagliflozin

For dosing recommendations for patients with moderate or severe hepatic impairment section 4.2. A single dose (10 mg) dapagliflozin clinical pharmacology study was conducted in patients with mild, moderate or severe hepatic impairment (Child-Pugh classes A, B, and C, respectively) and healthy matched controls in order to compare the pharmacokinetic characteristics of dapagliflozin between these populations. There were no differences in the protein binding of dapagliflozin between patients with hepatic impairment compared to healthy subjects. In patients with mild or moderate hepatic impairment mean C_{max} and AUC of dapagliflozin were up to 12 % and 36 % higher, respectively, compared to healthy matched control subjects. These differences were not considered to be clinically meaningful and no dose adjustment from the proposed usual dose of 10 mg once daily for dapagliflozin is proposed for these populations. In patients with severe hepatic impairment (Child-Pugh class C), mean C_{max} and AUC of dapagliflozin were up to 40 % and 67 % higher than matched healthy controls, respectively. No dose adjustment is required for patients with severe hepatic impairment. However, the benefit:risk for the use of dapagliflozin in patients with severe hepatic impairment should be individually assessed since the safety and efficacy of dapagliflozin have not been specifically studied in this population.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Metformin hydrochloride

No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment.

Age

Dapagliflozin

No dosage adjustment for dapagliflozin from the dose of 10 mg once daily is recommended on the basis of age. The effect of age (young: ≥ 18 to < 40 years [$n=105$] and elderly: ≥ 65 years [$n=224$]) was evaluated as a covariate in a population pharmacokinetic model and compared to patients ≥ 40 to < 65 years using data from healthy subject and patient studies. The mean dapagliflozin systemic exposure (AUC) in young patients was estimated to be 10, 4 % lower than in the reference group [90 % CI: 87,9; 92,2 %] and 25 % higher in elderly patients compared to the reference group [90 % CI: 123; 129 %]. These differences in systemic exposure were considered not to be clinically meaningful.

Metformin hydrochloride

Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and C_{max} is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function.

Paediatric and adolescent

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Dapagliflozin

Pharmacokinetics in the paediatric and adolescent population have not been studied.

Metformin hydrochloride

After administration of a single oral metformin 500 mg tablet with food, geometric mean metformin C_{max} and AUC differed less than 5 % between paediatric type 2 diabetic patients (12-16 years of age) and gender- and weight-matched healthy adults (20-45 years of age), all with normal renal function.

Gender

Dapagliflozin

No dosage adjustment from the dose of 10 mg once daily is recommended for dapagliflozin on the basis of gender. Gender was evaluated as a covariate in a population pharmacokinetic model using data from healthy subject and patient studies. The mean dapagliflozin AUCs in females (n=619) was estimated to be 22 % higher than in males (n=634), (90 % CI:117,124).

Metformin hydrochloride

Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes when analysed according to gender (males=19, females=16). Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycaemic effect of metformin was comparable in males and females.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Race

Dapagliflozin

No dosage adjustment from the dapagliflozin dose of 10 mg once daily is recommended on the basis of race. Race (White, Black, or Asian) was evaluated as a covariate in a population pharmacokinetic model using data from healthy subject and patient studies. Differences in systemic exposures between these races were small. Compared to Whites (n=1 147), Asian subjects (n=47) had no difference in estimated mean dapagliflozin systemic exposures (90 % CI range 3,7 % lower, 1 % higher). Compared to Whites, Black subjects (n=43) had 4,9 % lower estimated mean dapagliflozin systemic exposures (90 % CI range 7,7 % lower, 3,7 % lower).

Metformin hydrochloride

No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 diabetes, the antihyperglycaemic effect was comparable in Whites (n=249), Blacks (n=51), and Hispanics (n=24).

Body Weight

No dose adjustments from the proposed dapagliflozin dose of 10 mg once daily is recommended on the basis of weight.

In a population pharmacokinetic analysis using data from healthy subject and patient studies, systemic exposures in high-body-weight subjects (≥ 120 kg, n=91) were estimated

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

to be 78,3 % (90 % CI: 78,2, 83,2 %) of those of reference subjects with body weight between 75 and 100 kg. This difference is considered to be small, therefore, no dose adjustment from the proposed dose of 10 mg dapagliflozin once daily in patients with type 2 diabetes mellitus patients with high body weight (≥ 120 kg) is recommended.

Subjects with low body weights (< 50 kg) were not well represented in the healthy subject and patient studies used in the population pharmacokinetic analysis. Therefore, dapagliflozin systemic exposures were simulated with a large number of subjects. The simulated mean dapagliflozin systemic exposures in low-body-weight subjects were estimated to be 29 % higher than subjects with the reference group body weight. This difference is considered to be small and based on these findings no dose adjustment from the proposed dose of 10 mg dapagliflozin once daily in type 2 diabetes mellitus patients with low body weight (< 50 kg) is recommended.

5.3 Preclinical safety data

No animal studies have been conducted with XIGDUO XR to evaluate carcinogenesis, mutagenesis, or impairment of fertility. The following data are based on the findings in the studies with dapagliflozin and metformin individually.

Carcinogenesis, mutagenesis, impairment of fertility

Dapagliflozin

There was no evidence of carcinogenicity with dapagliflozin in either mouse or rat carcinogenicity studies.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Dapagliflozin was negative in the Ames mutagenicity assay and was positive in a series of in vitro clastogenicity assays in the presence of S9 activation and at concentrations greater than or equal to 100 µg/mL. Dapagliflozin was negative for clastogenicity in a series of in vivo studies evaluating micronuclei or DNA repair in rats at exposure multiples greater than 2100-times the clinical dose.

There was no carcinogenicity or mutagenicity signal in animal studies, suggesting that dapagliflozin does not represent a genotoxic risk to humans.

Dapagliflozin had no effects on mating, fertility, or early embryonic development in treated male or female rats at exposure multiples less than or equal to 1708-times and 998-times the maximum recommended human dose in males and females, respectively.

Metformin hydrochloride

There was no evidence of carcinogenicity with metformin in either mouse or rat carcinogenicity studies. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day, approximately 4 times the maximum recommended human daily dose of 2 000 mg based on body-surface-area comparisons.

There was no evidence of a mutagenic potential of metformin.

Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body-surface-area comparisons.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

Teratogenicity and impairment of early development

Dapagliflozin

Direct administration of dapagliflozin to weanling juvenile rats, and indirect exposure during late pregnancy and lactation (time periods corresponding to the second and third trimesters of pregnancy with respect to human renal maturation), are each associated with increased incidence and/or severity of renal pelvic and tubular dilatations in progeny.

In a juvenile toxicity study, when dapagliflozin was dosed directly to young rats from postnatal day (PND) 21 until PND 90 at doses of 1, 15, or 75 mg/kg/day, renal pelvic and tubular dilatations were reported at all dose levels; pup exposures at the lowest dose tested were $\geq 15\times$ the MRHD. These findings were associated with dose-related increases in kidney weight and macroscopic kidney enlargement observed at all doses. The renal pelvic and tubular dilatations observed in juvenile animals did not fully reverse within the approximate 1- month recovery period.

In a separate study of pre-natal and postnatal development, maternal rats were dosed from gestation day (GD) 6 through PND 21 (also at 1, 15, or 75 mg/kg/day), and pups were indirectly exposed in utero and throughout lactation. (A satellite study was conducted to assess dapagliflozin exposures in milk and pups). Increased incidence or severity of renal pelvic dilatation was again observed in adult offspring of treated dams, although only at 75 mg/kg/day (associated maternal and pup dapagliflozin exposures were $1\ 415\times$ and $137\times$, respectively, the human values at the MRHD). Additional developmental toxicity was limited to dose-related reductions in pup body weights and observed only at doses ≥ 15 mg/kg/day

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

(associated with pup exposures that are $\geq 29\times$ the human values at the MRHD). Maternal toxicity was evident only at 75 mg/kg/day and limited to transient reductions in body weight and food consumption at dose initiation. The no-adverse-effect level (NOAEL) for developmental toxicity, 1 mg/kg/day, is associated with a maternal systemic exposure multiple that is approximately $19\times$ the human value at the MRHD.

In additional studies of embryo-foetal development in rats and rabbits, dapagliflozin was administered for intervals coinciding with the major periods of organogenesis in each species. Neither maternal nor developmental toxicities were observed in rabbits at any dose tested (20, 60, or 180 mg/kg/day); 180 mg/kg/day is associated with a systemic exposure multiple of approximately $1\ 191\times$ the MRHD. In rats, dapagliflozin was neither embryo-lethal nor teratogenic at doses up to 75 mg/kg/day ($1\ 441\times$ the MRHD). Doses ≥ 150 mg/kg/day ($\geq 2\ 344\times$ the human values at the MRHD) were associated with both maternal and developmental toxicities. Maternal toxicity included mortality, adverse clinical signs, and decrements in body weight and food consumption. Developmental toxicity consisted of increased embryo-foetal lethality, increased incidences of foetal malformations and skeletal variations, and reduced foetal body weights.

Malformations included a low incidence of great vessel malformations, fused ribs and vertebral centra, and duplicated manubria and sternal centra. Variations were primarily reduced ossifications.

Metformin hydrochloride

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the maximum recommended human daily dose of 2 000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of foetal concentrations demonstrated a partial placental barrier to metformin.

Animal toxicology

A 3-month rat study was conducted with the combination of dapagliflozin and metformin. No toxicity was observed at AUC exposures 52 and 1.4 times the MRHD for dapagliflozin and metformin, respectively.

Dapagliflozin

Most of the effects observed in pivotal repeat-dose toxicity studies in both rats and dogs were considered to be secondary to pharmacologically mediated increases in urinary glucose and included decreases in body weights and/or body-weight gains, increased food consumption, and increases in urine volumes due to osmotic diuresis. In rats, the most noteworthy nonclinical toxicity finding of increased trabecular bone and tissue mineralization (associated with increased serum calcium), was only observed at high-exposure multiples ($\geq 2\ 100\times$ ~ based on human exposures at the MRHD). There was no dose-limiting or target-organ toxicities identified in the 12-month dog study at exposure multiples of $\geq 3\ 200\times$ ~ the human exposure at the MRHD.

6. PHARMACEUTICAL PARTICULARS

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Module 1.3.1.1.1 PI - Approved

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Date of approval: 12 February 2025

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

6.1 List of excipients

Each film-coated tablet of XIGDUO XR contains 5 mg or 10 mg of dapagliflozin and 500 mg or 1000 mg of metformin and the following inactive ingredients.

Dapagliflozin layer for 5 mg and 10 mg FDCs: microcrystalline cellulose, lactose anhydrous (48 mg), crospovidone, silicon dioxide, and magnesium stearate.

Metformin Layer for 500 mg FDCs: carboxymethylcellulose sodium, hypromellose 2208, hypromellose 2910, microcrystalline cellulose, silicon dioxide, and magnesium stearate.

Metformin Layer for 1000 mg FDCs: carboxymethylcellulose sodium, hypromellose 2208, silicon dioxide, and magnesium stearate.

Coating: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, FD&C yellow #6/Sunset Yellow FCF aluminium lake (5/ 500 only) and iron oxides for other strengths (5/ 1000, 10/ 500 and 10/ 1000).

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 months (3 years)

XIGDUO XR 5 mg/ 500 mg: Store at or below 30 °C.

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd

Product Name: XIGDUO® XR

Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)

Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved

Date of approval: 12 February 2025

XIGDUO XR 5 mg/ 1000 mg: Store at or below 25 °C.

XIGDUO XR 10 mg/ 500 mg: Store at or below 30 °C.

XIGDUO XR 10 mg/ 1000 mg: Store at or below 30 °C.

Keep in the original packaging.

Do not remove the blister strips from the carton until required for use.

Store in a cool dry place away from direct sunlight.

6.4 Special precautions for storage

This medicine does not require any special storage conditions

6.5 Nature and contents of container

Aluminium/aluminium foil blisters packed in carton

Pack sizes:

Blister packs of 14, 28, 30, 56 and 60 tablets.

Not all pack sizes may be marketed

6.6 Special precautions for disposal and other handling

No special requirements. Do not dispose of unused medicine in drains or sewerage systems
(e.g. toilets)

7. HOLDER OF CERTIFICATE OF REGISTRATION

AstraZeneca Pharmaceuticals (Pty) Limited

Applicant: AstraZeneca Pharmaceuticals (Pty) Ltd
Product Name: XIGDUO® XR
Strength and Dosage Form: 5 mg/500 mg, 5 mg/1000 mg,
10 mg/500 mg, 10 mg/1000 mg (Tablet)
Registration numbers: 52/21.2/0414; 52/21.2/0415;
52/21.2/0412; 52/21.2/0413

Module 1.3.1.1.1 PI - Approved
Date of approval: 12 February 2025

Building 2, Northdowns Office Park

17 Georgian Crescent West, Bryanston

Johannesburg, 2191

TEL: +27 (0) 11 797-6000

FAX: +27 (0) 11 797-6001

e-mail address: SA.MEAMEDinfo@astrazeneca.com

8. REGISTRATION NUMBER(S)

XIGDUO XR 5 mg/ 500 mg (Tablets): 52/21.2/0414

XIGDUO XR 5 mg/ 1000 mg (Tablets): 52/21.2/0415

XIGDUO XR 10 mg/ 500 mg (Tablets): 52/21.2/0412

XIGDUO XR 10 mg/ 1000 mg (Tablets): 52/21.2/0413

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

20 April 2021

10. DATE OF REVISION OF THE TEXT

12 February 2025